
    
      This study is an open, single/multiple infusion, dose escalation/dose regimen finding study
      to assess the safety and pharmacokinetics of CAR-CLDN18.2 T cell therapy, and to obtain the
      preliminary efficacy results in subjects who have been diagnosed with advanced solid tumor
      with positive claudin 18.2 expression and failed to standard systemic treatment.
    
  